Literature DB >> 15093805

New-onset diabetes after transplantation.

Piero Marchetti1.   

Abstract

For many years new-onset diabetes after transplantation has been recognized as a complication of solid-organ transplantation, although its importance has been greatly underestimated. Studies have shown that the cumulative incidence of this condition in heart transplant recipients may reach 32% at 5 years, similar to that reported in kidney and liver transplant patients. Several factors predispose to increased risk for developing new-onset diabetes after transplantation, including age, ethnicity, family history of diabetes, obesity and immunosuppressive therapy. Corticosteroids are associated with the greatest risk of developing the condition. Tacrolimus is more diabetogenic than cyclosporine in kidney and liver transplant patients, but there are few data reporting the effects of these agents in heart transplant patients. In kidney transplant patients, diabetes is known to be a significant risk factor for cardiovascular disease post-transplant. Although this has yet to be demonstrated clearly in heart transplant patients, evidence suggests that new-onset diabetes after transplantation may play a role in the development of cardiac allograft vasculopathy (CAV). Because CAV is the major limitation to long-term survival in this population, it is clear that efforts should be made to reduce the risk of diabetes and treat this condition appropriately. Management of transplant recipients with new-onset diabetes after transplantation has been assisted by the recent publication of International Consensus Guidelines. The guidelines were developed to establish a standard definition and describe risk factors for new-onset diabetes after transplantation. Use of these guidelines will help to prospectively identify those at risk of developing new-onset diabetes after transplantation so that therapeutic strategies can be individualized early in the treatment regimen. These management approaches should help to lower the risk of new-onset diabetes after heart transplantation and reduce the possible long-term consequences of the condition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093805     DOI: 10.1016/j.healun.2004.03.007

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  16 in total

1.  New-Onset Diabetes Mellitus After Transplantation in a Cynomolgus Macaque (Macaca fasicularis).

Authors:  Kristin A Matthews; Makoto Tonsho; Joren C Madsen
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

2.  Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics.

Authors:  Dror Koltin; Lillian Sung; Ahmed Naqvi; Stacey L Urbach
Journal:  Support Care Cancer       Date:  2011-11-08       Impact factor: 3.603

3.  A novel case of diabetic muscle necrosis in a patient with cystic fibrosis-related diabetes.

Authors:  Sreelatha Chalasani; Shankar S Bettadahalli; Satya V Bhupathi; Vijay H Aswani
Journal:  Clin Med Res       Date:  2013-05-08

Review 4.  From genotype to human β cell phenotype and beyond.

Authors:  Piero Marchetti; Farooq Syed; Mara Suleiman; Marco Bugliani; Lorella Marselli
Journal:  Islets       Date:  2012-09-01       Impact factor: 2.694

5.  Impact of Insurance Type on Initial Rejection Post Heart Transplant.

Authors:  Khadijah Breathett; Shannon Willis; Randi E Foraker; Sakima Smith
Journal:  Heart Lung Circ       Date:  2016-07-18       Impact factor: 2.975

Review 6.  Recent advances in the pathogenesis and management of biliary atresia.

Authors:  Jessica A Zagory; Marie V Nguyen; Kasper S Wang
Journal:  Curr Opin Pediatr       Date:  2015-06       Impact factor: 2.856

Review 7.  Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?

Authors:  Francesca M Egidi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis.

Authors:  Ralf Schiel; Sebastian Heinrich; Thomas Steiner; Undine Ott; Günter Stein
Journal:  Clin Exp Nephrol       Date:  2005-06       Impact factor: 2.801

Review 9.  Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

Review 10.  Evidence against a physiologic role for acute changes in CNS insulin action in the rapid regulation of hepatic glucose production.

Authors:  Christopher J Ramnanan; Dale S Edgerton; Alan D Cherrington
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.